Drug: Pembrolizumab
NFEC-2022-248
Phase 2 other active
Quick answer
Drug: Pembrolizumab for Clear-cell Metastatic Renal Cell Carcinoma is a Phase 2 program (other) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hospital Authority, Hong Kong
- Indication
- Clear-cell Metastatic Renal Cell Carcinoma
- Phase
- Phase 2
- Modality
- other
- Status
- active